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Background: Mesenchymal stem cells (MSCs) are an attractive source of stem cells for clinical applications. These
cells exhibit a multilineage differentiation potential and strong capacity for immune modulation. Thus, MSCs are
widely used in cell therapy, tissue engineering, and immunotherapy. Because of important advantages, umbilical
cord blood-derived MSCs (UCB-MSCs) have attracted interest for some time. However, the applications of
UCB-MSCs are limited by the small number of recoverable UCB-MSCs and fetal bovine serum (FBS)-dependent
expansion methods. Hence, this study aimed to establish a xenogenic and allogeneic supplement-free expansion
protocol.
Methods: UCB was collected to prepare activated platelet-rich plasma (aPRP) and mononuclear cells (MNCs).
aPRP was applied as a supplement in Iscove modified Dulbecco medium (IMDM) together with antibiotics. MNCs
were cultured in complete IMDM with four concentrations of aPRP (2, 5, 7, or 10%) or 10% FBS as the control.
The efficiency of the protocols was evaluated in terms of the number of adherent cells and their expansion, the
percentage of successfully isolated cells in the primary culture, surface marker expression, and in vitro differentiation
potential following expansion.
Results: The results showed that primary cultures with complete medium containing 10% aPRP exhibited the
highest success, whereas expansion in complete medium containing 5% aPRP was suitable. UCB-MSCs isolated
using this protocol maintained their immunophenotypes, multilineage differentiation potential, and did not form
tumors when injected at a high dose into athymic nude mice.
Conclusion: This technique provides a method to obtain UCB-MSCs compliant with good manufacturing practices
for clinical application.
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Clinical applicationIntroduction
Mesenchymal stem cells (MSCs) are one of the most
studied and applied types of stem cells to date. These
cells were first described by Friedenstein et al. as a cell
population similar to fibroblasts [1], which can differen-
tiate into multiple cell types such as osteoblasts, adipo-
cytes, and chondrocytes [2]. MSCs have been isolated
from many tissues including bone marrow [3,4], adipose* Correspondence: pvphuc@hcmuns.edu.vn
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unless otherwise stated.tissue [5-7], peripheral blood, umbilical cord blood (UCB)
[8-10], banked UCB [11-14], umbilical cords [15,16],
placenta [17], amniotic fluid [18], dental pulp [19], and
menstrual blood [20].
Compared with other stem cell sources, UCB-MSCs
have advantages such as non-invasive recovery, the
abundance of MSCs, and well-known characteristics. In
both pre-clinical and clinical settings, MSCs have been
studied to treat a various diseases. Pre-clinically, UCB-
MSCs have been used to treat neonatal brain injury [21],
fibrocartilaginous embolic myelopathy [22], spinal cordtd. This is an Open Access article distributed under the terms of the Creative
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[27], ischemia [28,29], hearing loss [30], damaged cor-
neal endothelium [31], Alzheimer’s disease [32], graft-
versus-host disease (GVHD) [33], acute hepatic necrosis
[34], diabetes mellitus [35], and liver cirrhosis [36]. Clin-
ically, UCB-MSCs have been transplanted for treatment
of autism [37], hereditary spinocerebellar ataxia [38], foot
disease in patients with type 2 diabetes mellitus [39], and
basilar artery dissection [40]. Clinical trials (retrieved from
clinicaltrial.gov) include mesenchymal stem cell transplant-
ation for engraftment of unrelated hematopoietic stem
cell transplantation (NCT00823316), treatment of steroid-
refractory acute or GVHD (NCT01549665), articular car-
tilage defect treatment (NCT01733186), and hematologic
malignancy treatment (NCT01854567).
The main concern in UCB-MSC applications is in vitro
expansion that is mostly affected by the culture medium.
For production protocols of UCB-MSCs under clinical
conditions, it is essential to include sterility controls, ana-
lysis for viral markers, and genetic testing such as karyo-
typing. Currently, UCB-MSCs can be produced at a GMP
(good manufacturing practice) grade by automated pro-
cessing protocols and some novel protocols. Procedures
have been developed to isolate mononuclear cells (MNCs)
in closed systems such as the SEPAX device [41,42]. Other
systems can also be used to expand MSCs such as the
Cell Stack System [43]. However, almost all of these
methods require fetal bovine serum (FBS) for culture. FBS-
based medium has some limitations associated with clinical
application, especially prion and viral transmission or adverse
immunological reactions against xenogenic components.
Some novel methods use human serum for MSC cul-
ture, especially platelet-rich plasma (PRP). Recent stud-
ies have used PRP from peripheral blood [44-48] and
UCB [49-52], which showed that PRP from peripheral
blood or UCB significantly stimulates the proliferation
of MSC from bone marrow [45,50], UCB [49,53], or adi-
pose tissue [44,54]. More importantly, MSCs cultured in
medium supplemented with PRP exhibit a normal pheno-
type and characteristics [49-52], and maintain their multi-
potency for differentiation into adipocytes, osteoblasts,
and chondrocytes. Taken together, these studies show that
PRP can replace FBS for in vitro MSC expansion.
All of these previous protocols have used allogeneic
PRP. The use of PRP allows MSCs to avoid xenogenic
immunological reactions, and prion and viral transmis-
sion, but MSCs may encounter human viral transmission
and immunological reactions induced by allogeneic com-
ponents. According to the European Medicines Agency
and regulation No. [EC] 1394/2007 of the European
Commission, MSC are considered as medicinal products
[55] and must be produced in compliance with GMP.
The GMP standards ensure that cells are produced with
the highest standards of sterility, quality control, anddocumentation following a standard operating proce-
dure. Therefore, in this study, we aimed to establish an
UCB-MSC isolation protocol using autologous PRP from
the same umbilical blood sample. This protocol is GMP
compliant and can be used for clinical applications.
Materials and methods
UCB collection and sample selection for study
UCB was collected from the umbilical cord vein with in-
formed consent of the mother. The collection was per-
formed in accordance with the ethical standards of the
local ethics committee. To eliminate differences between
UCB samples, the stem cell quantity was enumerated
based on the number of hematopoietic stem cells (HSCs)
using an Enumeration Pro-Count Kit (BD Bioscience)
following the manufacturer’s guidelines. Only samples
with ≥1 × 106 HSCs/ml were used in experiments.
MNC isolation and activated PRP preparation
First, blood samples were centrifuged at 2000 rpm for
15 min. The cell pellet was kept to isolate MNCs and
the plasma was collected and centrifuged at 3500 rpm
for 10 min. To prepare activated PRP (aPRP), a third of
the plasma volume and the platelet pellet was collected
and resuspended, and then 100 μL CaCl2 per 1 mL of
PRP was added to activate growth factor release. The
samples were then incubated at 37°C for 30 min or until
the occurrence of clotting. The centrifuged blood cells
were diluted at a ratio of 1:1 with phosphate buffered so-
lution (PBS) and then applied to density centrifugation
using Ficoll Hypaque (1.077 g/mL; Sigma-Aldrich, St
Louis, MO). The collected MNCs were washed twice
with PBS and then applied to experiments.
Primary culture
Twenty UCB samples were used for primary culture.
MNCs were cultured in Iscove modified Dulbecco medium
(IMDM) containing 1% antibiotic-mycotic (Sigma-Aldrich,
Louis St, MO), 10 ng/mL epidermal growth factor (EGF),
10 ng/mL basic fibroblast growth factor (bFGF), and vari-
ous concentrations of aPRP (2, 5, 7, or 10%) or 10% fetal
bovine serum (FBS) for the control. The cells were plated
at 5 × 104cells/mL in T-75 flasks (Corning) and incubated
at 37°C with 5% CO2. After 3 days of incubation, 6 mL of
fresh media were added to each flask. After 7 days, the
media were replaced with fresh media. Then, the media
was replaced every 4 days until the cells reached 70–80%
confluence. The efficiency of the media was evaluated by
the time required for adherent cells to appear and then
reach 70–80% confluence for the first subculture.
Secondary culture
After successful primary culture, the samples were sub-
cultured to evaluate the effects of the various media.
Pham et al. Journal of Translational Medicine 2014, 12:56 Page 3 of 10
http://www.translational-medicine.com/content/12/1/56The proliferation rate was evaluated by the eXCELLI-
gence system (Roche Applied Science, Indianapolis, IN).
A total of 1 × 103 cells were seeded into each well of a
96-well E-plate in triplicate. The culture plates were
placed into the eXCELLIgence system and incubated at
37°C with 5% CO2. Cell proliferation was monitored for
300 h with fresh medium changes every third day. Both
the cell doubling time and slope value were determined
by the software of the eXCELLIgence system.
Flow cytometry
Cell markers were analyzed following a previously pub-
lished protocol [11]. Briefly, cells were washed twice in
PBS containing 1% bovine serum albumin (Sigma-Aldrich).
The cells were then stained with anti-CD13-FITC, anti-
CD14-FITC, anti-CD34-FITC, anti-CD44-PE, anti-CD45-
FITC, anti-CD73-FITC, anti-CD90-PE, anti-CD105-FITC,
anti-CD106-PE, anti-CD166-PE, or anti-HLA-DR-FITC
antibodies (all purchased from BD Biosciences, San Jose,
CA). Stained cells were analyzed by a FACSCalibur flow
cytometer (BD Biosciences). Isotype controls were used in
all analyses.
In vitro differentiation
For differentiation into adipogenic cells, UCB-MSCs
were differentiated as described previously [9]. Briefly,
passage 5 cells were plated at 1 × 104 cells/well in 24-
well plates. At 70% confluence, the cells were cultured
for 21 days in IMDM containing 0.5 mmol/L 3-isobutyl-
1-methyl-xanthine, 1 nmol/L dexamethasone, 0.1 mmol/L
indo-methacin, and 10% FBS (all purchased from Sigma-
Aldrich). Adipogenic differentiation was evaluated by
observing lipid droplets in cells under a microscope.
For differentiation into osteogenic cells, UCB-MSCs
were plated at 1 × 104 cells/well in 24-well plates. At
70% confluence, the cells were cultured for 21 days in
IMDM containing 10% FBS, 10-7 mol/L dexamethasone,
50 μmol/L ascorbic acid-2 phosphate, and 10 mmol/L
β-glycerol phosphate (all purchased from Sigma-Aldrich)
[9]. Osteogenic differentiation was confirmed by Alizarin
red staining.Figure 1 UCB-MSC candidates adhered and exhibited a particular sha
all media. However, the highest numbers of cells appeared in 10% FBS (A)
decreased in 7% (D), 5% (C) and 2% aPRP (B).For differentiation into chondrogenic cells, UCB-MSCs
were induced to differentiate by a commercial medium for
chondrogenesis (StemPro Chondrogenesis Differentiation
Kit, A10071-01; Life Technologies). UCB-MSCs were dif-
ferentiated in pellet form according to the manufacturer’s
guidelines. After 21 days, the cell pellets were stained with
an anti-aggrecan monoclonal antibody (BD Biosciences).
Tumorigenicity assay
The tumorigenicity of UCB-MSCs was examined in athy-
mic nude mice. All manipulations of mice were approved
by the Local Ethics Committee of Stem Cell Research and
Application, University of Science (Ho Chi Minh city,
Vietnam). Each mouse was injected subcutaneously with
5 × 106 cells (three mice per group). As a positive control,
the mice were also injected with breast cancer cells at a
different site. Tumor formation in mice was followed up
for 3 months.
Statistical analysis
The significance of differences between mean values was
assessed by t-tests and analysis of variance. A P-value of
less than 0.05 was considered to be significant. All data
were analyzed by Prism 6 software.
Results
Primary cell culture
We collected 30 UCB samples of which 20 were applied
to experiments. For primary culture, MNCs from the
same sample were divided and cultured in five different
media containing 10% FBS or 2, 5, 7, or 10% aPRP. There
were differences in the time needed for MNCs to adhere
and exhibit a particular shape in the various media. For
example, at 72 h post-plating, there were clear diffe-
rences in the number of adhered and fibroblast-like
cells (Figure 1). The trend among the various media indi-
cated that the number of cells gradually increased in 2,
5, 7, or 10% aPRP or 10% FBS in that order. The data
from the 20 samples are presented in Figure 2.
As shown in Figure 2A, fibroblast-like cells appeared
the most rapidly in 10% aPRP (46.20 ± 8.94 h), whichpe. After 72 h of culture, adherent UCB-MSC candidates appeared in
and 10% aPRP (E), and the number of adherent cells gradually
Figure 2 Timing of adherence and confluence of primary cultured cells. In 10% aPRP, MNCs adhered the soonest, and the adherence time
gradually increased as the concentration of aPRP was decreased gradually (A). Consequently, the time needed to reach 70–80% confluence in
10% aPRP was the shortest, which gradually increased as the concentration of aPRP decreased gradually (B).
Figure 3 Cell proliferation in the various media as recorded by
the exCelligence method. The results showed that the proliferation
rates of cells in 5, 7, or 10% aPRP, or 10% FBS were not significantly
different, while there was a significant difference in 2% aPRP.
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10.59 h), 5% aPRP (60.60 ± 10.64 h), 2% aPRP (61.80 ±
10.50 h), and 10% FBS (52.80 ± 12.56 h). These results
showed that increases of the aPRP concentration led to
decreases in the time needed for MNCs to adhere and
exhibit a fibroblastic shape, indicating that components
of aPRP were important for adherence and proliferation
of UCB-MSCs.
These times also dictated the number of days until
the first subculture (Figure 2B). As a result, 70–80%
confluence was reached at 23.35 ± 4.73 days in 10%
aPRP, whereas 25.50 ± 4.62, 30.40 ± 5.05, 30.40 ± 5.05,
and 26.55 ± 7.05 days were required in 7, 5, or 2%
aPRP, or 10% FBS, respectively.
Cell proliferation rates in the various media
After subculture, five samples were used to evaluate the
effects of the various media on UCB-MSC proliferation.
The results are presented in Figure 3. The proliferation
rates of the cells in the various media were recorded
from 0 to 300 h. At 0–130 h, the proliferation rates
among the media were not significantly different. How-
ever, from 130 to 260 h, the proliferation rates were signifi-
cantly different in 5, 7, or 10% aPRP, or 10% FBS compared
with that in 2% aPRP. From 260 to 300 h, cells in all the
various media underwent contact inhibition and death. As
shown in Figure 3, the proliferation rate of cells in 10%
aPRP was higher than that in the other media but the
difference was not significant.
We also compared the cell doubling times and slope
values (Figure 4). The doubling time is the time needed
for the cell population to double in number. There were
no differences in the doubling times for the whole
period from 0 to 300 h. However, there were significant
changes at each period from 0 to 130 h and 130 to
260 h. In the early stage (0–130 h), the doubling times
were similar between the media (24.9 ± 6.11, 22.6 ± 4.9,
28.1 ± 5.71, 27.6 ± 5.52, and 25.5 ± 6.48 h in 10% FBS or2, 5, 7, or 10% aPRP, respectively) (P < 0.05). In the next
period (from 130 to 260 h), cells in all the various media
proliferated with increasing doubling times. At this
stage, the doubling times were similar in 5, 7, or 10%
aPRP (P < 0.05) (131 ± 2.51, 134 ± 3, and 134 ± 2.49 h in
5, 7, or 10% aPRP, respectively). In contrast, the doubling
time in 2% aPRP suddenly increased to 148 ± 3.63 h. In
10% FBS, the doubling time was 139 ± 2.82 h which was
lower than that in 2% aPRP but higher than that in 5, 7,
or 10% aPRP, but the difference was not significant.
These data further confirmed that the proliferation
rate of UCB-MSCs in 5, 7, or 10% aPRP were similar to
that in 10% FBS, but higher than that in 2% aPRP. The
slope values also supported these results. In the early
stage (0–130 h), there were no differences in the slope
values among the media (0.021 ± 0.001, 0.018 ± 0.001,
0.020 ± 0.001, 0.021 ± 0.001, and 0.021 ± 0.001 for 10%
FBS or 2, 5, 7, or 10% aPRP, respectively). In the next
stage (130–260 h), the slope values exhibited signifi-
cant differences between 10% FBS or 5, 7, or 10% aPRP
Figure 4 Doubling times and slope values in the various media. The values were obtained at three stages, 0–130 h, 130–260 h, and 260–300 h,
and the whole proliferation curve at 0–300 h. There were no significant differences between the doubling times (A) and slope values (B) in 5, 7, or
10% aPRP, or 10% FBS, but a significant difference in 2% aPRP.
Figure 5 Immunophenotypes of MSCs in the various media. The results include flow cytometric analysis of CD13, CD14, CD34, CD44, CD45,
CD73, CD90, CD105, CD106, CD166, and HLA-DR (A). Data were analyzed and presented in a graph (B).
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0.001, respectively) compared with that in 2% aPRP.
Phenotypes of MSCs
MSC-specific marker expression of UCB-MSCs cultured
in the various media were evaluated and compared as
presented in Figure 5. The results showed that UCB-
MSCs in all the media exhibited a MSC-specific marker
profile, positivity for CD13, CD44, CD73, CD90, CD105,
CD106, and CD166, and negativity for CD14, CD34,
CD45, and HLA-DR. The expression levels of positive
markers in MSCs were similar among the media.
UCB-MSCs cultured in the various media were exa-
mined for their capacity to differentiate into adipogenic,
osteogenic, and chondrogenic lineages. The results of
differentiation assays are presented in Figures 6 and 7.
In all media, the cells successfully differentiated into adi-
pocytes, osteoblasts, and chondrocytes. Compared with
cells prior to induction (Figure 6A–E), cells in all media
accumulated lipid droplets in their cytoplasm after induc-
tion with adipocyte differentiation medium (Figure 6F–K).
Following induction with osteoblast differentiation medium,
cells in all media accumulated Ca2+ and Mg2+ in the cyto-
plasm and extracellular matrix, which were stained with
Alizarin red (Figure 6I–P). After 21 days of chondrogenic
differentiation, cells in all media expressed aggrecan,
a cartilage-specific proteoglycan core protein (Figure 7).
Tumorigenicity of UCB-MSCs
UCB-MSCs cultured in the various media were injected
into athymic nude mice. Breast cancer cells were alsoFigure 6 MSCs cultured in the various media maintain their potential fo
the control (A, B, C, D, and E are 10% FBS or 2, 5, 7, or 10% aPRP, respectively
induction (F, G, H, I, and K are 10% FBS or 2, 5, 7, or 10% aPRP, respectively). F
differentiated into osteoblasts that were positive for Alizarin red staining (L, Minjected at a different location as a positive control. In-
jection of UCB-MSCs resulted in no tumor formation,
whereas injection of breast cancer cells resulted in
tumor formation in all mice (Figure 8).
Discussion
The aim of this study was to establish a GMP-compliant
protocol for isolation of UCB-MSC for clinical application.
Therefore, we eliminated xenogenic and allogeneic com-
ponents that can cause immunological reactions and viral
transmission. Our approach replaced FBS in the medium
with autologous aPRP that was isolated from the same
UCB sample used to isolate MNCs.
Because the source of autologous aPRP was limited
and the necessary number of MSCs for clinical applica-
tion is high, we evaluated four concentrations of aPRP in
complete medium, including 2, 5, 7, and 10%, and 10%
FBS as a control. The effects of aPRP on MSC prolifera-
tion was evaluated in primary and secondary cultures. In
primary culture, medium containing 10% aPRP signifi-
cantly stimulated MSC proliferation compared with that
of the other aPRP concentrations and 10% FBS. In
medium containing 10% aPRP, MSCs adhered quickly and
proliferated rapidly. These observations demonstrated that
aPRP contains all the essential components similar to those
in FBS for support of cell attachment and proliferation. In
fact, aPRP contains high amounts of attachment proteins
such as fibrin, fibronectin, vitronectin, and thrombospon-
din [49,56]. In addition, aPRP contains several growth
factors that stimulate cell proliferation, such as EGF,
acidic fibroblast growth factor, keratinocyte growth factor,r differentiation into adipocytes and osteoblasts. Compared with
), MSCs accumulated lipid droplets in their cytoplasm after 21 days of
ollowing induction with osteoblast differentiation medium, the cells
, N, O, and P are 10% FBS or 2, 5, 7, or 10% aPRP, respectively).
Figure 7 MSCs cultured in the various media can differentiate into chondrocytes. Differentiated cells (A, E, I, R, and N are 10% FBS or 2, 5, 7,
or 10% aPRP, respectively) were stained with Hoescht 33342 B, F, K, O, and S are 10% FBS or 2, 5, 7, or 10% aPRP, respectively) and an anti-aggrecan
monoclonal antibody (C, G, L, P and T are 10% FBS or 2, 5, 7, or 10% aPRP, respectively). Merged images with brightfield as shown in D, H, M, Q,
and U for 10% FBS or 2, 5, 7, or 10% aPRP, respectively.
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factor, hepatocyte growth factor, and bFGF [49,52,57].
Compared with bovine growth factors in FBS, aPRP can
be obtained from humans, allowing better interactions be-
tween growth factors and cell receptors. In primary cul-
ture, the time needed to reach confluency in 10% aPRP
indicated that this concentration of aPRP induced stron-
ger MSC proliferation than that of FBS.
In expansion culture, the effects of the four concentra-
tions of aPRP were also evaluated alongside the 10% FBS
control. The results showed that there were no differencesbetween 5, 7, or 10% aPRP supplementation compared with
10% FBS, but these aPRP concentrations showed signifi-
cantly different effects than those of 2% aPRP. In fact, we
confirmed these effects by the proliferation curve, doub-
ling time, and slope value for proliferation. Based on pro-
liferation curves, we could easily recognize differences in
the proliferation rates between 2% aPRP and the other
aPRP concentrations. However, the proliferation rates in
5, 7, or 10% aPRP or 10% FBS were not increased signifi-
cantly. These data indicated the differences in the growth
factor concentrations at 5, 7 and 10% aPRP did not cause
Figure 8 Tumorigenicity of UCB-MSCs in athymic nude mice. MSCs from all groups (10% FBS (A) or 2 (B), 5 (C), 7 (D), or 10% aPRP (E)) could
not cause tumors in the athymic nude mice while breast cancer cells easily caused tumors when injected in the same mice. MSCs were injected
in the left breast; and breast cancer cells were injected in the left breast.
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MSCs.
Other important properties that we evaluated were
the effects of aPRP-containing medium on surface marker
expression and multilineage differentiation of UCB-MSCs.
We used the marker profile of positive and negative
markers suggested by Domicini et al. [58]. The results
showed that UCB-MSCs maintained their marker expres-
sion in aPRP-containing media compared with that in
medium supplemented with FBS. UCB-MSCs cultured
in aPRP- and FBS-containing media did not express
hematopoietic markers, such as CD14, CD34 and CD45,
or HLA-DR, while they expressed stromal cell markers
such as CD13, CD44, CD73, CD90, CD105, and CD106.
These results completely agreed with other studies of UCB-
MSCs cultured in FBS-supplemented medium [8,9,59-61],
human peripheral blood-derived PRP [62], and UCB-
derived PRP [49-51]. UCB-MSCs cultured in the various
media also exhibited multilineage differentiation to adi-
pocytes, osteoblasts, and chondrocytes. These results
were similar to those of UCB-MSCs isolated in serum-
supplemented medium [8,9,59-61].
Some previous studies have shown that PRP has some
effects on MSCs. In addition to PRP strongly stimulating
MSC proliferation, PRP also triggers differentiation. How-
ever, these effects of PRP are different between the vari-
ous types of MSCs. PRP induces UCB-MSCs and bone
marrow-derived MSCs to differentiate into osteoblasts
[46], [53,63] and adipose-derived stem cells to differentiate
into chondrocytes [7]. In this study, we did not evaluate
the effects of PRP on UCB-MSC differentiation. However,
we found that MSCs cultured in medium containing 2, 5,
7, or 10% aPRP maintained their potential for differenti-
ation into adipocytes, osteoblasts, and chondrocytes. This
result indicated that aPRP cultured UCB-MSCs had not
become mature cells such as osteoblasts or chondrocytes.
In fact, in previous studies, although MSCs have been pro-
posed to differentiate into osteoblasts and chondrocytes,
they also maintain their differentiation capacity for adipo-
cytes, osteoblasts, and chondrocytes [62,64]. In our finalanalysis, UCB-MSCs cultured in the various media were
examined for tumorigenicity in athymic nude mice. The
results showed that all mice injected with UCB-MSCs cul-
tured in the various media showed no tumor formation at
the injection site, while cancer cells caused tumor forma-
tion in all mice at their injection site.
In summary, we successfully established a protocol for
isolation of GMP-compliant UCB-MSCs. For primary
culture, IMDM plus 10% aPRP is appropriate. For ex-
pansion, culture medium plus 5% aPRP is suitable. This
protocol complies with GMP because of its xenogenic-
and allogeneic-free medium components.
Conclusion
UCB is a rich source of MSCs. UCB-MSCs can be isolated
with xenogenic and allogeneic component-free medium. In
this study, we successfully established a GMP-compliant
UCB-MSC isolation protocol. Autologous aPRP can be
used to replace FBS. Both aPRP and MNCs can be isolated
from the same blood sample. In primary culture, MNCs
should be cultured in IMDM plus 10% aPRP and 1%
antibiotic-mycotic. However, in expansion culture, MSCs
should be cultured in IMDM plus 5% aPRP and 1%
antibiotic-mycotic. MSCs isolated by this protocol prolifer-
ate similarly as those in 10% FBS, maintain MSC pheno-
types such as expression of CD13, CD44, CD73, CD90,
CD105, CD106, and CD166, and do not express CD14,
CD34, CD45, or HLA-DR. They also maintain their multi-
lineage differentiation potential for adipocytes, osteoblast,
and chondrocytes. In particular, the isolated MSCs do not
form tumors at a high dose in athymic nude mice. This
promising protocol is suitable for clinical applications of
UCB-MSCs in the near future.
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